CHRS - Coherus BioSciences, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Redwood City,
United States
Type: Equity
CHRS price evolution
CHRS
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $159.24 | $259.77 | $102.89 | |
| Short term investments | $14.86 | |||
| Net receivables | $198.8 | $313.57 | $284.14 | $260.52 |
| Inventory | $47.64 | $62.16 | $127.62 | $130.1 |
| Total current assets | $369.02 | $557.93 | $627.48 | $475.63 |
| Long term investments | ||||
| Property, plant & equipment | $2.91 | $3.33 | $4.19 | $5.12 |
| Goodwill & intangible assets | $55.45 | $57.1 | $71.67 | |
| Total noncurrent assets | $116.92 | $136.07 | $153.97 | |
| Total investments | $14.86 | |||
| Total assets | $505 | $674.86 | $763.54 | $629.6 |
| Current liabilities | ||||
| Accounts payable | $21.89 | $76.82 | $69.06 | $35.22 |
| Deferred revenue | ||||
| Short long term debt | $175 | |||
| Total current liabilities | $295.57 | $463 | $538.3 | $331.77 |
| Long term debt | $264.51 | $264.1 | $304.35 | $478.7 |
| Total noncurrent liabilities | $295.96 | $307.09 | $491.26 | |
| Total debt | $268.26 | $479.35 | $478.7 | |
| Total liabilities | $592.97 | $758.96 | $845.39 | $823.03 |
| Shareholders' equity | ||||
| Retained earnings | -$1500.3 | -$1489.55 | -$1476.63 | -$1579.5 |
| Other shareholder equity | -$0.28 | -$0.27 | -$0.27 | -$0.25 |
| Total shareholder equity | -$84.11 | -$81.84 | -$193.43 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $102.89 | $63.55 | $417.19 | $541.16 |
| Short term investments | $14.86 | $128.13 | ||
| Net receivables | $260.52 | $109.96 | $123.02 | $157.05 |
| Inventory | $130.1 | $38.79 | $93.25 | $92.19 |
| Total current assets | $475.63 | $381.23 | $602.32 | $767.48 |
| Long term investments | $0.44 | |||
| Property, plant & equipment | $5.12 | $14.44 | $7.81 | $20.06 |
| Goodwill & intangible assets | $71.67 | $5.93 | $3.56 | $3.56 |
| Total noncurrent assets | $153.97 | $99.61 | $77.01 | $74.17 |
| Total investments | $14.86 | $128.13 | $0.44 | |
| Total assets | $629.6 | $480.85 | $679.33 | $841.65 |
| Current liabilities | ||||
| Accounts payable | $35.22 | $11.53 | $16.16 | $15.2 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $331.77 | $138.69 | $165.33 | $145.65 |
| Long term debt | $478.7 | $472.48 | $415.53 | $413.97 |
| Total noncurrent liabilities | $491.26 | $479.57 | $416.28 | $415.02 |
| Total debt | $478.7 | $476.1 | $415.53 | $413.97 |
| Total liabilities | $823.03 | $618.26 | $581.61 | $560.67 |
| Shareholders' equity | ||||
| Retained earnings | -$1579.5 | -$1341.61 | -$1049.85 | -$762.75 |
| Other shareholder equity | -$0.25 | -$0.25 | -$0.27 | -$0.27 |
| Total shareholder equity | -$193.43 | -$137.42 | $97.73 | $280.97 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $70.77 | $64.98 | $77.06 | $91.52 |
| Cost of revenue | $28.37 | $34.59 | $84.57 | |
| Gross Profit | $50.03 | $36.61 | $42.48 | $6.96 |
| Operating activities | ||||
| Research & development | $21.95 | $28.47 | $26.37 | |
| Selling, general & administrative | $35.16 | $56.53 | $49.49 | |
| Total operating expenses | $56.42 | $57.12 | $85 | $75.86 |
| Operating income | -$20.51 | -$42.52 | -$68.91 | |
| Income from continuing operations | ||||
| EBIT | -$7.59 | $113.99 | -$69.03 | |
| Income tax expense | ||||
| Interest expense | -$5.36 | $5.33 | $11.12 | $10.62 |
| Net income | ||||
| Net income | -$10.75 | -$12.92 | $102.88 | -$79.65 |
| Income (for common shares) | -$12.92 | $102.88 | -$79.65 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $257.24 | $211.04 | $326.55 | $475.82 |
| Cost of revenue | $158.99 | $70.08 | $57.59 | $37.67 |
| Gross Profit | $98.25 | $140.96 | $268.96 | $438.16 |
| Operating activities | ||||
| Research & development | $109.44 | $199.36 | $363.11 | $142.76 |
| Selling, general & administrative | $192.01 | $198.48 | $169.71 | $139.08 |
| Total operating expenses | $301.45 | $397.84 | $532.82 | $281.84 |
| Operating income | -$203.2 | -$256.88 | -$263.86 | $156.32 |
| Income from continuing operations | ||||
| EBIT | -$197.73 | -$259.28 | -$264.14 | $156.87 |
| Income tax expense | -$0.38 | $3.46 | ||
| Interest expense | $40.54 | $32.47 | $22.96 | $21.17 |
| Net income | ||||
| Net income | -$237.89 | -$291.75 | -$287.1 | $132.24 |
| Income (for common shares) | -$237.89 | -$291.75 | -$287.1 | $132.24 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$12.92 | $102.88 | -$79.65 | |
| Operating activities | ||||
| Depreciation | $1.19 | $1.51 | $1.52 | |
| Business acquisitions & disposals | $187.82 | |||
| Stock-based compensation | $7.23 | $7.32 | $10.8 | |
| Total cash flows from operations | $59.73 | -$46.77 | -$12.94 | |
| Investing activities | ||||
| Capital expenditures | $0.04 | |||
| Investments | $40 | $14.89 | $36.21 | |
| Total cash flows from investing | $230.86 | $27.66 | $202.76 | $35.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.63 | $1.8 | $0.89 | |
| Net borrowings | -$186.77 | |||
| Total cash flows from financing | -$187.21 | -$187.93 | $0.89 | $0.37 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$5.39 | -$100.53 | $156.88 | $22.63 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$237.89 | -$291.75 | -$287.1 | $132.24 |
| Operating activities | ||||
| Depreciation | $6.27 | $3.7 | $5.66 | $4.97 |
| Business acquisitions & disposals | $7 | -$37.43 | -$136 | -$7.5 |
| Stock-based compensation | $43.11 | $50.74 | $51.36 | $38.16 |
| Total cash flows from operations | -$174.88 | -$241.12 | -$37.43 | $154.15 |
| Investing activities | ||||
| Capital expenditures | $0.56 | -$2.04 | -$1.29 | -$7.06 |
| Investments | $138.13 | -$127.38 | -$1.12 | $0.15 |
| Total cash flows from investing | $144.64 | -$166.85 | -$138.41 | -$14.4 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $74.22 | $9.37 | $54.3 | $21.23 |
| Net borrowings | $49.93 | -$0.67 | $203.6 | |
| Total cash flows from financing | $69.6 | $54.33 | $51.88 | $223.95 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $39.36 | -$353.65 | -$123.96 | $363.69 |
News
Fundamentals
| Market cap | $161.30M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 115.21M |
| Revenue | $304.34M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$450.00K |
| Revenue Q/Q | -5.09% |
| Revenue Y/Y | 44.19% |
| P/E ratio | -358.44 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.53 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.00 |
|---|---|
| ROA | -0.07% |
| ROE | N/A |
| Debt/Equity | -4.26 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.25 |
| Quick ratio | 1.09 |